obstetrical and gynelogical conditions |
||||||
|
obstetrical and gynelogical conditions News for 23-Dec-25 Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet Asthma General Source: MedicineNet Diabetes General Source: MedicineNet Asthma General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet Asthma General
|
The Best obstetrical and gynelogical conditions websiteAll the obstetrical and gynelogical conditions information you need to know about is right
here. Presented and researched by http://www.medical-mailings.com. We've searched
the information super highway far and wide to provide you with the
best obstetrical and gynelogical conditions site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
obstetrical and gynelogical conditions
Knowing you're getting value for money is very important in buying obstetrical and gynelogical conditions, so by coming to this web site you can rest with the sound knowledge that you are getting the obstetrical and gynelogical conditions you paid for. By buying through our recommend links you can also rest assured your obstetrical and gynelogical conditions will be of the highest quality. How do we know? Because when we're shopping for obstetrical and gynelogical conditions ourselves it's where we go. You might wonder why we're suggesting you click on some outside links rather than stay on our obstetrical and gynelogical conditions site. Well it's because we've only just put this site up and haven't yet got it fully operational. Our aim is to be the best site for obstetrical and gynelogical conditions info on the net, and I'm sure that one day soon we'll achieve it. So please bookmark us and come back soon. Meanwhile please follow one of the links. obstetrical and gynelogical conditions
obstetrical and gynelogical conditions information exists in a large variety of formats and genres (facts, opinions, obstetrical and gynelogical conditions stories, interpretations and so on). This information has been created to inform, persuade and educate you on all that you ever need to know about obstetrical and gynelogical conditions. The quality ranges from poor to brilliant with lots of shades in between. This website has been developed from painstaking research covering all areas of obstetrical and gynelogical conditions. We undertook this research initially for ourselves because we have a genuine interest in obstetrical and gynelogical conditions. We now wish to share this information with you so that you can directly benefit from our research. When you click on our links and follow our leads you can be confident that we have trod the road ahead and discovered the highest quality information. -Saving Pediatric Drug Becomes Readily Available to Those in Need by: ARA Content
(ARA) - We can all sympathize with the frustration people experience waiting for a new drug that is being tested for a certain disorder. Imagine you have a child with a rare disorder and the only drug effective for treating the disorder is not only extremely hard to obtain, but available only through a nationally-administered random selection process. For many American families, this dilemma is a harsh reality. Patients suffering from a host of difficult to treat orphan disorders have found marked relief from using HP Acthar Gel. Some disorders Acthar helps include seizure complex in babies and young children, referred to as West's syndrome or infantile spasm; Still's disease and ulcerative colitis; Bell's palsy; multiple sclerosis; adrenocortical insufficiency and non-endocrine disorders that are responsive to glucocorticoids. For the past four years, however, the drug has only been available through a limited access program administered by the National Organization for Rare Disorders (NORD), a federation of more that 135 non-profit health organizations serving people with rare disorders. U.S. physicians who were interested in obtaining Acthar Gel for their patients with life-threatening or severely debilitating conditions who did not respond to any other treatment were given first access to the drug. Others with "non-life-threatening" cases had to enroll in a computerized random selection process administered by NORD. An estimated 1,600 patients, primarily suffering from West's syndrome and multiple sclerosis who experience episodes of "flare," have been allowed access to HP Acthar Gel each year for the past four years under the limited access program. More than 5,000 additional patients whose physicians requested the drug were denied. The origins of this drug shortage crisis date back to 1996 when Aventis Pharmaceuticals stopped making Acthar for a few months because of manufacturing difficulties. But now, Questcor Pharmaceuticals, Inc. (AMEX: QSC) has signed an agreement with Aventis to acquire the worldwide rights to HP Acthar Gel. Questcor has also reached a manufacturing agreement with Aventis and will gradually move production to an independent manufacturing facility. As a result, HP Acthar Gel is now back in full production and is returning to normal levels of distribution. Questcor began shipments of HP Acthar Gel to wholesalers the last week of September 2001, giving patients in need access to the product. "We are delighted that Questcor is making this critically important product more widely available after this long period of restricted distribution," said Abbey S. Meyers, president of NORD. "We have been working closely with the company over the last several months to ensure that anyone with a need for Acthar Gel is now able to readily receive the product through more traditional channels. Too many people have suffered as a result of limited access to Acthar Gel." Questcor Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company that serves the needs of acute and critical care hospitals with its proprietary products. Visit www.questcor.com for more information on the company and its products. If you are a patient with a disorder that can be treated with Acthar, ask your doctor to contact Questcor Pharmaceuticals at (510) 400-0700. For more information about Acthar, including distribution information, please visit www.Acthar.com.
|
|||||
|
http://www.gomailings.com/ |
||||||
| Medical Presentations Medical Presentations MD Newscast |